GENEART again among Germany's Top "Technology Fast 50" Companies
* Reuters is not responsible for the content in this press release.
REGENSBURG, GERMANY, Oct 23 (MARKET WIRE) --
- GENEART among the top 15 of the fastest growing technology
companies in Germany
- Among life science companies of this competition, GENEART ranks
second
- Cumulative corporate growth exceeds 800 percent over the past five
years
- Targeted investing in automation and process technologies allows
further increase in capacities
Regensburg, October 23, 2008 - Above average growth in net sales
earns GENEART No. 11 ranking in Deloitte's "Technology Fast 50" award of
the fastest growing technology companies in Germany. The 50 winners of
the growth prize awarded by audit and business consulting service
provider Deloitte presented themselves in Dusseldorf last night. Rankings
are based on cumulative net sales growth in percent over the past five
years. GENEART, publicly traded global leader in gene synthesis and
specialist in the field of Synthetic Biology, lifted net sales growth by
more than 800 percent to EUR 12.3 million over this period. Among life
science companies GENEART ranked second in this competition.
"GENEART targeted investments in automation and process technologies over
the past two years, which lifted production to a whole new level. Our
capacities will increase fivefold by the end of 2010. These expanded
capacities reflect the increased demand for synthetic genes, which
emerged more and more from a niche to a mass product", stated Christian
Ehl, CEO of GENEART AG.
For further inquiries, please contact:
Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-638
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com
Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de
Legal Information
This document may contain estimates, prognoses and opinions about company
plans and objectives, products or services, future results, opinions
about these results or opinions leading up to these results. All these
projections into the future are subject to risk, uncertainty and
unforeseeable change outside the control of the GENEART Group. Many
factors may lead to actual results, which considerably deviate from the
given projections for these results.
About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since become
the global market leader. Today, the company is one of the leading
specialists in the Synthetic Biology field. Experts at GENEART provide
key technologies for the development and production of new therapeutics
and vaccines. Customers also take advantage of GENEART services to
customize enzyme attributes, such as the attributes of enzymes used as
detergent additives, and to construct bacteria, which produce complex
biopolymers or break down polymers, such as synthetics, petroleum
components, etc. Our production and service spectrum spans a wide range,
from the production of synthetic genes according to DIN EN ISO 9001-2000,
to the creation of gene libraries in the combinatorial biology, to the
development and production of DNA-based biologically active substances.
The GENEART AG in Regensburg (Germany) and the subsidiaries GENEART Inc.
in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ more
than 190 people. Since May 2006, GENEART is listed on the German Stock
Exchange.
About Deloitte
Deloitte provides services in areas of auditing, tax consulting,
corporate and financial consulting for companies and institutions from
all industries. With a network of member companies in 140 countries,
Deloitte connects first-class services with comprehensive regional market
competency, and thus assists clients to succeed all over the world. "To
be the Standard of Excellence" is both shared vision and individual
aspiration for Deloitte's 165,000 employees. Here, Deloitte refers to
Deloitte Touche Tohmatsu, an association under Swiss law, and/or its
network of member companies. Each member company is legally distinct and
independent. A detailed description of the legal structure of Deloitte
Touche Tohmatsu and its member companies can be found at
www.deloitte.com/de/UeberUns Copyright 2008 Deloitte & Touche GmbH
Wirtschaftspruefungsgesellschaft.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright Copyright Hugin AS 2008. All rights reserved.
Copyright 2008, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters